

**DRUGS FOR NEGLECTED DISEASES INITIATIVE  
NORTH AMERICA, INC.**

***FINANCIAL STATEMENTS AND  
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS***

**DECEMBER 31, 2023**

# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## *TABLE OF CONTENTS*

---

|                                                                                                              | <u>Page</u> |
|--------------------------------------------------------------------------------------------------------------|-------------|
| REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS                                                           | 1-2         |
| FINANCIAL STATEMENTS                                                                                         |             |
| <i>Statements of Financial Position,</i><br>December 31, 2023 And 2022                                       | 3           |
| <i>Statement of Activities And Changes in Net Assets,</i><br>Year Ended December 31, 2023 And 2022           | 4           |
| <i>Schedule of Functional Expenses,</i><br>Year Ended December 31, 2023 With Summarized Information For 2022 | 5           |
| <i>Statements of Cash Flows,</i><br>Years Ended December 31, 2023 And 2022                                   | 6           |
| <i>Notes to Financial Statements</i>                                                                         | 7-11        |

---

---

## REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

**Board of Directors  
Drugs For Neglected Diseases Initiative North America, Inc.  
New York, New York**

### *Opinion*

We have audited the accompanying financial statements of Drugs for Neglected Diseases Initiative North America, Inc. (“*DNDi NA*”) (a nonprofit organization), which comprise the statement of financial position as of December 31, 2023 and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of DNDi NA as of December 31, 2023, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

### *Basis for Opinion*

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of DNDi NA and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### *Responsibilities of Management for the Financial Statements*

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about DNDi NA’s ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

### *Auditor’s Responsibilities for the Audit of the Financial Statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

**Board of Directors  
Drugs For Neglected Diseases Initiative North America, Inc.  
New York, New York**

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of DNDi NA's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about DNDi NA's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit

***Report on Summarized Comparative Information***

We have previously audited DNDi NA's 2022 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated July 12, 2023. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2022 is consistent, in all material respects, with the audited financial statements from which it has been derived.

*Tait, Weller & Baker LLP*

**New York, New York  
October 8, 2024**

# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## STATEMENT OF FINANCIAL POSITION

December 31, 2023 And 2022

---

|                                             | <u>2023</u>         | <u>2022</u>         |
|---------------------------------------------|---------------------|---------------------|
| <b>ASSETS</b>                               |                     |                     |
| Cash and cash equivalents                   | \$ 1,792,054        | \$ 819,629          |
| Contributions receivable                    | 24,041              | 10,000              |
| Grants receivable                           | -                   | 266,520             |
| Prepaid expenses and other assets           | 3,666               | 4,460               |
| Right-of-use asset <i>(Note 4)</i>          | <u>-</u>            | <u>54,846</u>       |
| <b>Total assets</b>                         | <u>\$ 1,819,761</u> | <u>\$ 1,155,455</u> |
| <br>                                        |                     |                     |
| <b>LIABILITIES</b>                          |                     |                     |
| Accounts payable and other accrued expenses | \$ 271,718          | \$ 104,888          |
| Grants payable                              | 357,197             | -                   |
| Payroll liabilities                         | 86,321              | 64,828              |
| Lease liability <i>(Note 4)</i>             | <u>-</u>            | <u>59,846</u>       |
| <b>Total liabilities</b>                    | <u>715,236</u>      | <u>229,562</u>      |
| <br>                                        |                     |                     |
| <b>NET ASSETS</b>                           |                     |                     |
| Without donor restrictions                  | 934,525             | 925,893             |
| With donor restrictions <i>(Note 6)</i>     | <u>170,000</u>      | <u>-</u>            |
| <b>Total net assets</b>                     | <u>1,104,525</u>    | <u>925,893</u>      |
| <br>                                        |                     |                     |
| <b>Total liabilities and net assets</b>     | <u>\$ 1,819,761</u> | <u>\$ 1,155,455</u> |

# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS

Year Ended December 31, 2023 And 2022

|                                        | <u>Without Donor<br/>Restrictions</u> | <u>With Donor<br/>Restrictions</u> | <u>2023<br/>Total</u> | <u>2022<br/>Total</u> |
|----------------------------------------|---------------------------------------|------------------------------------|-----------------------|-----------------------|
| <b>Revenue and Other Support</b>       |                                       |                                    |                       |                       |
| Contributions <i>(Note 2)</i>          | \$ 3,950,892                          | \$ -                               | \$ 3,950,892          | \$ 3,659,059          |
| ERC Credit <i>(Note 9)</i>             | -                                     | -                                  | -                     | 59,419                |
| Foundations                            | 215,057                               | 170,000                            | 385,057               | 190,077               |
| Interest income                        | <u>14,987</u>                         | <u>-</u>                           | <u>14,987</u>         | <u>23,387</u>         |
| <b>Total revenue and other support</b> | <u>4,180,936</u>                      | <u>170,000</u>                     | <u>4,350,936</u>      | <u>3,931,942</u>      |
| <b>Expenses</b>                        |                                       |                                    |                       |                       |
| Program services                       | <u>2,939,521</u>                      | <u>-</u>                           | <u>2,939,521</u>      | <u>2,815,140</u>      |
| <b>Total program services</b>          | <u>2,939,521</u>                      | <u>-</u>                           | <u>2,939,521</u>      | <u>2,815,140</u>      |
| Supporting services                    |                                       |                                    |                       |                       |
| Management and general                 | 482,348                               | -                                  | 482,348               | 560,482               |
| Fundraising                            | <u>750,435</u>                        | <u>-</u>                           | <u>750,435</u>        | <u>477,449</u>        |
| <b>Total supporting services</b>       | <u>1,232,783</u>                      | <u>-</u>                           | <u>1,232,783</u>      | <u>1,037,931</u>      |
| <b>Total expenses</b>                  | <u>4,172,304</u>                      | <u>-</u>                           | <u>4,172,304</u>      | <u>3,853,071</u>      |
| <b>Change in net assets</b>            | 8,632                                 | 170,000                            | 178,632               | 78,871                |
| <b>Net Assets</b>                      |                                       |                                    |                       |                       |
| Beginning of year                      | <u>925,893</u>                        | <u>-</u>                           | <u>925,893</u>        | <u>847,022</u>        |
| <b>End of year</b>                     | <u>\$ 934,525</u>                     | <u>\$ 170,000</u>                  | <u>\$ 1,104,525</u>   | <u>\$ 925,893</u>     |

# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## STATEMENT OF FUNCTIONAL EXPENSES

For The Year Ended December 31, 2023 With Summarized Information For 2022

|                                | 2023                |                              |                   | 2022                |                     |
|--------------------------------|---------------------|------------------------------|-------------------|---------------------|---------------------|
|                                | Program<br>Services | Management<br>And<br>General | Fundraising       | Total               | Total               |
| Salaries and Benefits          | \$ 875,811          | \$ 389,249                   | \$ 356,812        | \$ 1,621,872        | \$ 1,549,692        |
| Grant – Research & Development | 1,714,645           | -                            | -                 | 1,714,645           | 1,777,205           |
| Communications and Education   | 139,590             | -                            | 308,282           | 447,872             | 249,641             |
| Professional Fees              | 37,166              | 16,518                       | 15,142            | 68,826              | 84,154              |
| Transportation and Travel      | 56,404              | 25,068                       | 22,979            | 104,451             | 66,537              |
| Rent                           | 25,920              | 11,520                       | 10,560            | 48,000              | 44,000              |
| IT and Telephone               | 3,850               | 1,711                        | 1,569             | 7,130               | 8,080               |
| Office Supplies and Other      | 65,832              | 29,258                       | 26,820            | 121,910             | 53,874              |
| Conferences and Events         | 14,564              | 6,473                        | 5,933             | 26,970              | 8,945               |
| Insurance                      | 1,820               | 809                          | 741               | 3,370               | 3,216               |
| Bank Fees                      | <u>3,919</u>        | <u>1,742</u>                 | <u>1,597</u>      | <u>7,258</u>        | <u>7,727</u>        |
| <b>Total Expenses – 2023</b>   | <u>\$ 2,939,521</u> | <u>\$ 482,348</u>            | <u>\$ 750,435</u> | <u>\$ 4,172,304</u> |                     |
| <b>Total Expenses – 2022</b>   | <u>\$ 2,815,140</u> | <u>\$ 560,482</u>            | <u>\$ 477,449</u> |                     | <u>\$ 3,853,071</u> |

# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## STATEMENT OF CASH FLOWS

Year Ended December 31, 2023 And 2022

|                                                                                                     | <u>2023</u>         | <u>2022</u>       |
|-----------------------------------------------------------------------------------------------------|---------------------|-------------------|
| <b>INCREASE IN CASH</b>                                                                             |                     |                   |
| <i>Change in net assets</i>                                                                         | \$ 178,632          | \$ 78,871         |
| <i>Adjustments to reconcile change in net assets<br/>to net cash used for operating activities:</i> |                     |                   |
| Amortization of right-of-use asset                                                                  | 54,846              | 43,649            |
| Interest on lease liability                                                                         | -                   | 351               |
| Operating lease liability                                                                           | (59,846)            | (39,000)          |
| (Increase) decrease in assets                                                                       |                     |                   |
| Contributions receivable                                                                            | (14,041)            | (10,000)          |
| Grants receivable                                                                                   | 266,520             | (266,520)         |
| Prepaid expenses and other assets                                                                   | 794                 | 15,413            |
| Increase (decrease) in liabilities                                                                  |                     |                   |
| Accounts payable                                                                                    | 166,830             | 72,847            |
| Grants payable                                                                                      | 357,197             | (390,488)         |
| Payroll liabilities                                                                                 | <u>21,493</u>       | <u>(38,266)</u>   |
| <b>Net cash provided by (used for) operating activities</b>                                         | 972,425             | (533,143)         |
| <i>Cash and cash equivalents</i>                                                                    |                     |                   |
| Beginning of year                                                                                   | <u>819,629</u>      | <u>1,352,772</u>  |
| <b>End of year</b>                                                                                  | <u>\$ 1,792,054</u> | <u>\$ 819,629</u> |
| <b>SUPPLEMENTAL DISCLOSURE</b>                                                                      |                     |                   |
| Right-of-use asset in exchange for new financing liability                                          | <u>\$ -</u>         | <u>\$ 98,495</u>  |



# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## NOTES TO FINANCIAL STATEMENTS

December 31, 2023 And 2022

---

### (1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### **ORGANIZATION AND PURPOSE**

Drugs for Neglected Diseases Initiative North America, Inc. (“**DNDi NA**”) is a not-for-profit organization whose primary purpose is to conduct activities that support or benefit the Drugs for Neglected Diseases Initiative (Geneva, Switzerland) (“**DNDi**”). These activities include making grants to support programs, projects and activities of DNDi that (1) stimulate and support research and development primarily of drugs, as well as vaccines and diagnostics for neglected diseases; (2) promote equitable access and development of new drugs, new formulations of existing drugs, and encourage production of known effective drugs, diagnostic methods and/or vaccines for neglected diseases; (3) adopt new treatments for neglected diseases to meet patient needs, as well as to meet the requirements of delivery and production capacity in developing countries; and (4) raise awareness of the need to research and develop drugs for neglected diseases.

#### **ACCOUNTING ESTIMATES**

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management makes estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates.

#### **CASH AND CASH EQUIVALENTS**

DNDi NA considers money market funds to be cash equivalents.

#### **REVENUE RECOGNITION**

DNDi NA recognizes contributions when cash, securities or other assets; an unconditional promise to give; or a notification of a beneficial interest is received. Conditional promises to give – that is, those with a measurable performance or other barrier and right of return – are not recognized until the conditions on which they depend have been met. DNDi NA reports gifts of cash and other assets as restricted support if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as “net assets released from restriction”. Revenue that is restricted by the donor is recorded as increases without donor restriction if the restrictions expire in the fiscal year in which the revenue was recorded. Gifts-in-kind are recorded at fair value on the date of receipt.

#### **NET ASSETS**

Net assets are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of DNDi NA are classified and reported as follows:

**Without donor restrictions** – Net assets that are not subject to donor-imposed stipulations and that may be expendable for any purpose in performing the primary mission of the DNDi NA.

**With donor restrictions** – Net assets that are subject to donor-imposed stipulations. As the restrictions are satisfied, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported as “net assets released from restrictions.” There were no net assets with donor restrictions as of December 31, 2022 and 2021.

# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## NOTES TO FINANCIAL STATEMENTS – (Continued)

December 31, 2023 And 2022

---

### ***INCOME TAXES***

DNDi NA is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code (the “Code”), and has been classified as an organization, which is not a private foundation under Section 509(a) of the Code.

Management has reviewed the tax positions for each of the open tax years (2020 – 2022) or expected to be taken on DNDi NA’s 2023 tax return and has concluded that there are no significant uncertain tax positions that would require recognition in the financial statements.

### ***FUNCTIONAL ALLOCATION OF EXPENSES***

The financial statements report certain categories of expenses that are attributable to more than one program or supporting function. These expenses require allocation on a reasonable basis that is consistently applied. DNDi’s expenses are allocated based on analysis of time and effort.

### ***PRIOR YEAR INFORMATION***

The financial statements include certain prior year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with generally accepted accounting principles. Accordingly, such information should be read in conjunction with DNDi NA’s financial statements for the year ended December 31, 2022, from which the summarized information was derived.

## **(2) CONCENTRATIONS**

DNDi NA receives annual funding from DNDi in Geneva, Switzerland and from another not-for-profit organization. For the years ended December 31, 2023 and 2022, these sources of revenue comprise approximately 83% of the total funding of DNDi NA for each year.

## **(3) CONTRIBUTION AND GRANTS RECEIVABLE/PAYABLE**

Contributions receivable at December 31, 2023 are due to be received within one year, while grants receivable/payable at December 31, 2023 are due to be received/paid within one year.

## **(4) LEASES**

As of December 31, 2022, DNDi NA leased office space in New York, New York under a lease agreement with an initial term greater than 12 months. DNDi NA determined whether an agreement is or contained a lease at lease inception. Right-of-use assets represent DNDi NA’s right to use an underlying asset for the lease term and lease liabilities represent DNDi NA’s obligation to make lease payments arising from the lease, measured at an amount equal to the present value of the minimum lease payments over the remaining expected term of the lease. Amortization expense and interest expense related to DNDi NA’s finance leases are included in occupancy and office expense on the statement of functional expenses.

In determination of the lease term, DNDi NA considers the likelihood of lease renewal options and lease termination provisions.

# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## NOTES TO FINANCIAL STATEMENTS – (Continued)

December 31, 2023 And 2022

---

The discount rate for a lease is derived from the rate implicit in the lease whenever readily determinable or DNDi NA's incremental borrowing rate.

The following quantitative data related to DNDi NA's operating lease for the year ended December 31, 2022 is as follows:

**Operating Lease Amounts:**

|                     |           |
|---------------------|-----------|
| Right-of-use assets | \$ 54,846 |
| Lease liabilities   | 59,846    |

**Other Information:**

|                                                    |            |
|----------------------------------------------------|------------|
| Operating outgoing cash flows for operating leases | \$ 39,000  |
| Weighted-average remaining lease term              | 1.25 years |
| Weighted average discount rate                     | .44%       |

Lease cost information for the year ended December 31, 2022 is as follows:

|                                                 |                  |
|-------------------------------------------------|------------------|
| Operating lease cost, excluding sublease income | <u>\$ 44,000</u> |
|-------------------------------------------------|------------------|

### (5) COMMITMENTS

DNDi NA leases office space under a lease agreement that runs through March 31, 2024. In March of 2024 the lease was extended for three months through June 30, 2024. Monthly rent payments under the lease are \$4,000 per month. Rent expense for the year ended December 31, 2023 was \$48,000. Future minimum lease payments under the lease is as follows at December 31, 2023:

| <u>Year Ending December 31,</u> | <u>Amount</u>   |
|---------------------------------|-----------------|
| 2024                            | <u>\$24,000</u> |

### (6) NET ASSETS

Net assets with donor restrictions are available for the following purposes at December 31, 2023 and 2022:

|                        | <u>2021</u>       | <u>2020</u> |
|------------------------|-------------------|-------------|
| Time restricted grants | <u>\$ 170,000</u> | <u>\$ -</u> |

# DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.

## NOTES TO FINANCIAL STATEMENTS – (Continued)

December 31, 2023 And 2022

---

### (7) FINANCIAL ASSETS AND LIQUIDITY RESOURCES

DNDi NA strives to maintain liquid financial assets to be available as its general expenditures, liabilities and other obligations become due. Financial assets in excess of daily cash requirements are invested in money market funds and other short-term investments.

The following table reflects DNDi NA's financial assets as of December 31, 2023 and 2022, reduced by amounts that are not available to meet general expenditures within one year of the statement of financial position date because of contractual restrictions. Amounts not available to meet general expenditures within one year may include net assets with donor and/or contractual restrictions.

|                                                                         | <u>2023</u>         | <u>2022</u>         |
|-------------------------------------------------------------------------|---------------------|---------------------|
| <b>Financial Assets</b>                                                 |                     |                     |
| Cash and cash equivalents                                               | \$ 1,792,054        | \$ 819,629          |
| Contributions receivable                                                | 24,041              | 10,000              |
| Grants receivable                                                       | <u>-</u>            | <u>266,520</u>      |
| Total financial assets                                                  | 1,816,095           | 1,096,149           |
| Less:                                                                   |                     |                     |
| Grants payable                                                          | <u>(357,197)</u>    | <u>-</u>            |
| Financial assets available to meet general expenditures within one year | <u>\$ 1,458,898</u> | <u>\$ 1,096,149</u> |

### (8) PENSION PLAN

DNDi NA has a plan qualified under Section 403(b) that covers all eligible employees. Contributions to the plan are made at the discretion of the Board of Directors and are limited to 9% of the employee's annual salary.

During the years ended December 31, 2023 and 2022, DNDi NA made contributions of \$92,181 and \$87,581, respectively.

### (9) CARES ACT

Under the provisions of the Coronavirus Aid, Relief, and Economic Security Act (the "**CARES Act**") signed into law on March 27, 2020 and the subsequent extension of the CARES Act, DNDi NA believed that it was eligible for a refundable employee retention credit. The tax credit is equal to 50% of qualified wages paid to employees during a quarter, capped at \$10,000 of qualified wages per employee through December 31, 2020. Additional relief provisions were passed by the United States government, which extend and slightly expand the qualified wage caps on these credits through December 31, 2021. Based on these additional provisions, the tax credit is now equal to 70% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee has been increased to \$10,000 of qualified wages per quarter. During the fiscal year ended December 31, 2022, DNDi NA recorded revenue of \$59,419 related to the CARES Employee Retention Credit ("**ERC**") which is included on the Consolidated Statement of Activities and Changes in Net Assets.

The ERC program are subject to audit by the Federal Government for eligibility and related costs.

**DRUGS FOR NEGLECTED DISEASES INITIATIVE NORTH AMERICA, INC.**

***NOTES TO FINANCIAL STATEMENTS – (Continued)***

**December 31, 2023 And 2022**

---

**(10) SUBSEQUENT EVENTS**

Subsequent events after the balance sheet date through the date that the financial statements were available for issuance, October 8, 2024, have been evaluated in the preparation of the financial statements.